Iopidine (Apraclonidine)

Apraclonidine acts as a selective alpha‑2 adrenergic receptor agonist in the eye. By stimulating these receptors on the ciliary body, it reduces aqueous humor production and simultaneously increases uveoscleral outflow, leading to a net decrease in intra‑ocular pressure. This dual action helps control pressure‑related damage in glaucomatous conditions.

The dosing regimen for Iopidine is determined by the prescribing ophthalmologist based on the individual’s condition, severity, and response to therapy. Typically, one or two drops are instilled in the affected eye(s) once or twice daily, but the exact frequency and duration must be set by the healthcare provider.

Safety data for apraclonidine in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Because systemic absorption can occur, it should be used only if the potential benefit justifies any possible risk to the fetus or infant. Consultation with a physician is essential before use in these populations.

To request Iopidine, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required cold‑chain handling), and assistance with import documentation.

Iopidine (apraclonidine) is an alpha‑2 agonist, whereas many first‑line agents such as prostaglandin analogues (e.g., latanoprost) primarily increase uveoscleral outflow, and beta‑blockers (e.g., timolol) reduce aqueous production via beta‑receptor blockade. Apraclonidine offers a complementary mechanism and may be used as adjunct therapy when monotherapy does not achieve target pressure, but its side‑effect profile differs, with more frequent ocular irritation.

Iopidine should be stored at temperatures below 25 °C, protected from direct sunlight, moisture, and freezing. Keep the bottle tightly closed when not in use and retain it in the original packaging. Do not use the solution after the expiration date or if the solution becomes discolored or contains particles.

Iopidine is applied topically as an eye drop. The patient should wash their hands, tilt the head back, pull down the lower eyelid to create a small pocket, and instill the prescribed number of drops into the conjunctival sac. After administration, close the eye gently and avoid blinking excessively for a few seconds to allow absorption. Do not touch the dropper tip to the eye or any surface.

Although uncommon, serious adverse events can include severe allergic reactions such as angioedema or anaphylaxis, significant systemic hypotension especially when combined with other antihypertensive agents, and rare cases of corneal epithelial defects that may threaten vision. Patients should be instructed to seek immediate medical attention if they experience swelling of the face, throat, sudden drop in blood pressure, or worsening visual symptoms.

Iopidine is contraindicated in individuals with known hypersensitivity to apraclonidine or any excipients in the formulation. Caution is advised for patients with severe cardiovascular disease, uncontrolled low blood pressure, or those already receiving systemic alpha‑blockers. It should also be avoided in patients with active ocular infections or inflammation unless directed by an ophthalmologist.